一、主要会计数据和财务指标 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -0.1400 | -0.1700 | 17.65 | 0.3000 | | 每股净资产（元） | 10.23 | 10.95 | -6.58 | 17 | | 每股公积金(元) | 9.06 | 9.06 | 0 | 13.08 | | 每股未分配利润(元) | -0.05 | 0.68 | -107.35 | 2.62 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.03 | 0.05 | -40 | 1.06 | | 净利润(亿元) | -0.18 | -0.21 | 14.29 | 0.36 | | 净资产收益率(%) | -1.39 | -1.58 | 12.03 | 2.46 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 9429.17万股，累计占流通股比： 76.5 ...

金迪克公告，2024年营业收入8080.27万元，同比下降39.96%。归属于上市公司股东的净亏损9350.28万 元，去年同期净亏损7099.03万元。基本每股收益-0.76元／股。公司拟不派发现金红利，不送红股，不 以公积金转增股本，剩余未分配利润结转至下一年度。 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-005 江苏金迪克生物技术股份有限公司 2024 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2024年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以公司2024年年度的定期报告为准，提请投资者注意投资风险。 一、2024 年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（％） | | --- | --- | --- | --- | | 营业总收入 | 8,080.27 | 13,459.14 | -39.96 | | 营业利润 | -11,372.03 | -7,468.90 | 不适用 | | 利润总额 | -11,507.74 | -8,657.40 | 不适用 | | 归属于母公司所有者的净利润 | -9,349.66 | -7,099.03 | 不适用 | | 归属于母公司所有者的扣除非 经常性损益的净利润 | -10,665.25 | -7,257.09 ...

证券代码：688670 证券简称：金迪克 公告编号：2025-001 江苏金迪克生物技术股份有限公司 第二届监事会第九次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 2025 年 1 月 18 日 经与会监事审议，做出如下决议： （一）审议通过《关于 2024 年度计提资产减值准备的议案》 经审议，公司监事会认为本次计提资产减值准备符合《企业会计准则》及 公司相关会计政策的规定，符合公司实际情况。计提存货跌价减值准备后，能 够更加客观、公允地反映公司的财务状况和经营成果；本次计提减值准备决策 程序规范，符合法律法规和《公司章程》的规定，不存在损害公司和全体股东 利益的情形，同意公司本次计提资产减值准备。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 特此公告。 江苏金迪克生物技术股份有限公司 监事会 江苏金迪克生物技术股份有限公司（以下简称"公司"）第二届监事会第九 次会议通知于 2025 年 1 月 14 日以电子邮件方式送达，并于 2025 年 1 月 17 日 ...

财联社1月17日电，金迪克公告，预计2024年度营业收入为8000万元到9000万元，比上年同期减少 4459.14万元到5459.14万元，同比下降33.13%到40.56%。 预计实现归属于母公司所有者的净利润为-1亿元到-9000万元，比上年同期减少1900.97万元到2900.97万 元，同比下降26.78%到40.86%。 ...

Financial Projections - The company expects 2024 annual revenue to be between 80 million and 90 million CNY, a decrease of 44.59 million to 54.59 million CNY from the previous year, representing a year-on-year decline of 33.13% to 40.56%[3] - The projected net profit attributable to the parent company for 2024 is expected to be between -100 million and -90 million CNY, a decrease of 19.0097 million to 29.0097 million CNY from the previous year, reflecting a year-on-year decline of 26.78% to 40.86%[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between -110 million and -100 million CNY, a decrease of 27.4291 million to 37.4291 million CNY from the previous year, indicating a year-on-year decline of 37.80% to 51.58%[3] Vaccine Production and Development - The company plans to accelerate the production, approval, and sales of influenza vaccines in 2025 to capture market opportunities for the 2025-2026 flu season[8] - A new workshop for influenza vaccine production is under construction, with multiple production lines expected to be operational by April 2026, which will enhance capacity and shorten production cycles[8] - The company is focusing on expanding its vaccine product line, particularly in the influenza vaccine sector, with a current vaccination rate in China around 3%, significantly lower than the nearly 50% rate in Europe and the US[11] - The company is committed to enhancing its research and development efforts, with a significant increase in R&D investment compared to the previous year[12] Revenue Impact and Challenges - The company has adjusted the prices of its quadrivalent influenza vaccines, which has negatively impacted current revenue[9] - The company anticipates a total asset impairment provision of approximately 24.0325 million CNY for unsellable influenza vaccines due to their approaching expiration[9] Sales Network - The company has established a sales network covering over 2,000 district and county-level disease control centers across the country[13]

江苏金迪克生物技术股份有限公司 舆情管理制度 第一章 总则 第一条 为提高江苏金迪克生物技术股份有限公司（以下简称"公司"）应对 各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公 司股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权 益，根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规则》《上 海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等相关法律、 行政法规、规章、规范性文件和《江苏金迪克生物技术股份有限公司章程》（以下 简称"《公司章程》"）的有关规定，结合公司的实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较大 影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种 ...

公司前次于 2021 年通过高新技术企业认定，有效期三年，本次系公司原高 新技术企业证书有效期满后进行的重新认定。根据《中华人民共和国企业所得 税法》《中华人民共和国企业所得税法实施条例》等相关规定，公司自本次通过 高新技术企业认定后，连续三年内将继续享受高新技术企业所得税优惠政策， 按 15%的税率缴纳企业所得税。 证券代码：688670 证券简称：金迪克 公告编号：2024-032 江苏金迪克生物技术股份有限公司 关于自愿披露公司通过高新技术企业重新认定的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据全国高新技术企业认定管理工作领导小组办公室于 2024 年 12 月 3 日发 布的《对江苏省认定机构 2024 年认定报备的第一批高新技术企业进行备案的公 告》，江苏金迪克生物技术股份有限公司（以下简称"公司"）被列入江苏省 2024 年第一批备案的高新技术企业名单，再次通过了高新技术企业认定。证书 编号为：GR202432000687，发证日期为 2024 年 11 月 6 日，有效期三年。 董事会 202 ...

Financial Performance - The company's revenue for Q3 2024 was ¥35,611,056.15, a decrease of 67.81% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was a loss of ¥12,594,311.40, with a year-to-date loss of ¥53,461,400.63[3]. - The basic and diluted earnings per share for Q3 2024 were both -¥0.10[3]. - Total operating revenue for the first nine months of 2024 was CNY 38,899,225.52, a decrease of 67.8% compared to CNY 120,843,721.03 in the same period of 2023[15]. - Net profit for the first nine months of 2024 was a loss of CNY 53,461,400.63, compared to a loss of CNY 11,077,111.92 in the same period of 2023[17]. - Basic and diluted earnings per share for the first nine months of 2024 were both CNY -0.43, compared to CNY -0.09 in the same period of 2023[17]. Research and Development - Research and development expenses totaled ¥7,062,085.62 for Q3 2024, representing 19.83% of revenue, a significant increase of 50.64 percentage points year-over-year[4]. - Research and development expenses for the first nine months of 2024 were CNY 15,684,998.97, an increase from CNY 12,049,272.55 in the same period of 2023[16]. Assets and Liabilities - The total assets at the end of Q3 2024 were ¥1,558,172,277.20, a decrease of 4.50% from the end of the previous year[4]. - The total equity attributable to shareholders at the end of Q3 2024 was ¥1,317,620,227.81, down 3.90% from the previous year[4]. - Total liabilities as of the end of the reporting period were CNY 240,552,049.39, down from CNY 260,519,676.81 at the end of the previous year[15]. - The total current assets amounted to ¥628,818,075.32, a decrease from ¥722,242,458.52 as of December 31, 2023, representing a decline of approximately 12.93%[13]. - The total assets of the company were CNY 1,558,172,277.20, a decrease from CNY 1,631,601,305.25 at the end of the previous year[15]. Cash Flow - The company reported a net cash flow from operating activities of -¥127,334,109.03 year-to-date, a decrease of 306.17% compared to the previous year[3]. - In the first three quarters of 2024, the net cash flow from operating activities was -127,334,109.03 RMB, a significant decline compared to 61,761,430.14 RMB in the same period of 2023[18]. - Total cash inflow from operating activities was 50,815,849.54 RMB, down from 329,424,695.98 RMB year-over-year[18]. - The net increase in cash and cash equivalents was -36,038,778.50 RMB, contrasting with an increase of 255,840,622.91 RMB in the previous year[19]. - The ending balance of cash and cash equivalents was 34,404,810.28 RMB, down from 430,569,549.73 RMB year-over-year[19]. Sales and Market Conditions - The company experienced a significant decline in sales due to the temporary shutdown of its flu vaccine workshop in Q3 2023, resulting in no sales revenue for that period[4]. - The company attributed the decline in revenue to a decrease in flu vaccine sales and a price reduction for the 2024/2025 flu season products[8]. - The company reported a total revenue of 37,811,047.56 RMB from sales and services in the first three quarters of 2024, compared to 318,684,352.44 RMB in the same period of 2023[18]. Government Support - The company received government subsidies amounting to ¥58,150.02 during the reporting period, which were closely related to its normal business operations[5].

证券代码：688670 证券简称：金迪克 公告编号：2024-031 江苏金迪克生物技术股份有限公司 会议召开时间：2024 年 11 月 4 日（星期一）16:00-17:00 会议召开地点：上海证券交易所"上证路演中心"网络平台（网址： http://roadshow.sseinfo.com/） 会议召开方式：图文展示（可选）+网络文字互动方式 投资者可于 2024 年 11 月 1 日（星期五）17:00 前将有关问题通过电子 邮件、传真的形式发送至公司邮箱 gdk001@gdkbio.com。公司将在业绩说明会 上对投资者普遍关注的问题进行回答。 江苏金迪克生物技术股份有限公司（以下简称"公司"）于 2024 年 10 月 25 日在上海证券交易所网站（www.sse.com.cn）披露《江苏金迪克生物技术股份 有限公司 2024 年第三季度报告》。为便于广大投资者更加全面、深入地了解公 司 2024 年前三季度经营成果、财务状况，公司计划于 2024 年 11 月 4 日（星期 一）16:00-17:00 召开 2024 年第三季度业绩说明会，就各位投资者关心的问题进 行交流。 一、说明会类型 本次 ...